-
1
-
-
29544433211
-
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
-
DOI 10.1056/NEJMoa052258
-
Thürlimann B, Keshaviah A, Coates AS, et al: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757, 2005 (Pubitemid 43016814)
-
(2005)
New England Journal of Medicine
, vol.353
, Issue.26
, pp. 2747-2757
-
-
Thurlimann, B.1
Keshaviah, A.2
Coates, A.S.3
Mouridsen, H.4
Mauriac, L.5
Forbes, J.F.6
Paridaens, R.7
Castiglione-Gertsch, M.8
Gelber, R.D.9
Rabaglio, M.10
Smith, I.11
Wardly, A.12
Price, K.N.13
Goldhirsch, A.14
-
2
-
-
37449028688
-
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-Month analysis of the ATAC trial
-
Forbes JF, Cuzick J, Buzdar A, et al: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-Month analysis of the ATAC trial. Lancet Oncol 9:45-53, 2008
-
(2008)
Lancet Oncol
, vol.9
, pp. 45-53
-
-
Forbes, J.F.1
Cuzick, J.2
Buzdar, A.3
-
3
-
-
17444453765
-
Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women
-
DOI 10.1016/S0959-8049(03)00602-6
-
Thürlimann B, Robertson JF, Nabholtz JM, et al: Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer 39:2310-2317, 2003 (Pubitemid 37214855)
-
(2003)
European Journal of Cancer
, vol.39
, Issue.16
, pp. 2310-2317
-
-
Thurlimann, B.1
Robertson, J.F.R.2
Nabholtz, J.M.3
Buzdar, A.4
Bonneterre, J.5
-
4
-
-
0141836855
-
Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer
-
DOI 10.1093/annonc/mdg362
-
Paridaens R, Dirix L, Lohrisch C, et al: Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 14:1391-1398, 2003 (Pubitemid 37185285)
-
(2003)
Annals of Oncology
, vol.14
, Issue.9
, pp. 1391-1398
-
-
Paridaens, R.1
Dirix, L.2
Lohrisch, C.3
Beex, L.4
Nooij, M.5
Cameron, D.6
Biganzoli, L.7
Cufer, T.8
Duchateau, L.9
Hamilton, A.10
Lobelle, J.P.11
Piccart, M.12
-
5
-
-
38349098666
-
Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer
-
Rossi E, Morabito A, De Maio E, et al: Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer. J Clin Oncol 26:264-270, 2008
-
(2008)
J Clin Oncol
, vol.26
, pp. 264-270
-
-
Rossi, E.1
Morabito, A.2
De Maio, E.3
-
6
-
-
1542359096
-
Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer
-
DOI 10.1038/sj.bjc.6601557
-
Forward DP, Cheung KL, Jackson L, et al: Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 90:590-594, 2004 (Pubitemid 38297195)
-
(2004)
British Journal of Cancer
, vol.90
, Issue.3
, pp. 590-594
-
-
Forward, D.P.1
Cheung, K.L.2
Jackson, L.3
Robertson, J.F.R.4
-
7
-
-
60549097419
-
Endocrine therapy plus zoledronic acid in premenopausal breast cancer
-
Gnant M, Mlineritsch B, Schippinger W, et al: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691, 2009
-
(2009)
N Engl J Med
, vol.360
, pp. 679-691
-
-
Gnant, M.1
Mlineritsch, B.2
Schippinger, W.3
-
8
-
-
67349280302
-
Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer
-
Han HS, Ro J, Lee KS, et al: Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer. Breast Cancer Res Treat 115:335-342, 2009
-
(2009)
Breast Cancer Res Treat
, vol.115
, pp. 335-342
-
-
Han, H.S.1
Ro, J.2
Lee, K.S.3
-
9
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors
-
European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
-
Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
-
10
-
-
10744228140
-
CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment
-
DOI 10.1016/S1053-4296(03)00031-6
-
Trotti A, Colevas AD, Setser A, et al: CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176-181, 2003 (Pubitemid 36962641)
-
(2003)
Seminars in Radiation Oncology
, vol.13
, Issue.3
, pp. 176-181
-
-
Trotti, A.1
Colevas, A.D.2
Setser, A.3
Rusch, V.4
Jaques, D.5
Budach, V.6
Langer, C.7
Murphy, B.8
Cumberlin, R.9
Coleman, C.N.10
Rubin, P.11
-
12
-
-
0038460245
-
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group
-
DOI 10.1200/JCO.2003.04.194
-
Mouridsen H, Gershanovich M, Sun Y, et al: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21:2101-2109, 2003 (Pubitemid 46606358)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.11
, pp. 2101-2109
-
-
Mouridsen, H.1
Gershanovich, M.2
Sun, Y.3
Perez-Carrion, R.4
Boni, C.5
Monnier, A.6
Apffelstaedt, J.7
Smith, R.8
Sleeboom, H.P.9
Jaenicke, F.10
Pluzanska, A.11
Dank, M.12
Becquart, D.13
Bapsy, P.P.14
Salminen, E.15
Snyder, R.16
Chaudri-Ross, H.17
Lang, R.18
Wyld, P.19
Bhatnagar, A.20
more..
-
13
-
-
0030876075
-
An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer
-
DOI 10.1023/A:1005833811584
-
Crump M, Sawka CA, DeBoer G, et al: An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Res Treat 44:201-210, 1997 (Pubitemid 27296379)
-
(1997)
Breast Cancer Research and Treatment
, vol.44
, Issue.3
, pp. 201-210
-
-
Crump, M.1
Sawka, C.A.2
DeBoer, G.3
Buchanan, R.B.4
Ingle, J.N.5
Forbes, J.6
Meakin, J.W.7
Shelley, W.8
Pritchard, K.I.9
-
14
-
-
0028951579
-
A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in preand perimenopausal patients with advanced breast cancer
-
Jonat W, Kaufmann M, Blamey RW, et al: A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in preand perimenopausal patients with advanced breast cancer. Eur J Cancer 31A:137-142, 1995
-
(1995)
Eur J Cancer
, vol.31 A
, pp. 137-142
-
-
Jonat, W.1
Kaufmann, M.2
Blamey, R.W.3
-
15
-
-
0035862149
-
Combined tamoxifen and luteinuzing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials
-
Klijn JG, Blamey RW, Boccardo F, et al: Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. J Clin Oncol 19:343-353, 2001 (Pubitemid 32112845)
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.2
, pp. 343-353
-
-
Klijn, J.G.M.1
Blamey, R.W.2
Boccardo, F.3
Tominaga, T.4
Duchateau, L.5
Sylvester, R.6
Beex, L.V.A.M.7
Mauriac, L.8
Van, Z.J.A.9
Veyret, C.10
Wildiers, J.11
Jassem, J.12
Piccart, M.13
Burghouts, J.14
Becqaert, D.15
Seynaeve, C.16
Mignolet, F.17
Duchateau, L.18
Sylvester, R.19
Namer, M.20
Julien, J.P.21
Garcia, C.J.22
Dunser, M.23
Margreiter, R.24
Tjabbes, T.25
Roozendaal, K.J.26
Van, D.V.P.C.27
Nortier, J.W.R.28
Blamey, R.29
Howell, A.30
Forbes, J.31
Kaufmann, M.32
Nordenskjold, B.33
Kvinnsland, S.34
Wilson, R.G.35
Jonat, W.36
Kleeberg, U.R.37
Eiermann, W.38
Hilfrich, J.39
Weitzel, H.K.40
Glas, U.41
Rutqvist, L.E.42
Rudenstam, C.43
Sander, S.44
Ryden, S.45
Honsson, P.46
Lonning, P.E.47
Loven, L.48
Russell, I.S.49
Olweny, C.50
Byrne, J.J.51
Snyder, R.D.52
Coates, A.S.53
Lowenthal, R.M.54
Jeal, P.N.55
Dalley, D.N.56
Janicke, F.57
Kleine, W.58
Michel, R.T.59
Canobbio, L.60
Amoroso, D.61
Rubagotti, A.62
Bumma, C.63
D'Aprile, M.64
De, M.A.65
Di, C.A.66
Francini, G.67
Petrioli, R.68
Folco, U.69
Calligioni, E.70
Gallotti, P.71
Lopez, M.72
Mesiti, M.73
Pacini, P.74
Sassi, M.75
Sismondi, P.76
Zola, P.77
Ogita, M.78
Okazaki, M.79
Watanabe, T.80
Satomi, T.81
Hatazawa, C.82
Okuyama, N.83
Koyama, T.84
Kobayashi, M.85
Shimizu, T.86
Tabei, T.87
Sano, M.88
Makino, H.89
Ando, J.90
Kimura, M.91
Takeuchi, T.92
Aoyama, H.93
Koyama, H.94
Shin, E.95
Chou, G.96
more..
-
16
-
-
0037157603
-
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial
-
DOI 10.1016/S0140-6736(02)09088-8
-
Baum M, Budzar AU, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002 (Pubitemid 34694019)
-
(2002)
Lancet
, vol.359
, Issue.9324
, pp. 2131-2139
-
-
Baum, M.1
Buzdar, A.U.2
Cuzick, J.3
Forbes, J.4
Houghton, J.5
Klijn, J.G.M.6
Sahmoud, T.7
-
17
-
-
49949115926
-
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-Year follow-up of the ABCSG-12 bone-mineral density substudy
-
Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al: Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-Year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9:840-849, 2008
-
(2008)
Lancet Oncol
, vol.9
, pp. 840-849
-
-
Gnant, M.1
Mlineritsch, B.2
Luschin-Ebengreuth, G.3
-
18
-
-
24644434439
-
Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer
-
DOI 10.1200/JCO.2005.07.097
-
Lønning PE, Geisler J, Krag LE, et al: Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23:5126-5137, 2005 (Pubitemid 46224021)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.22
, pp. 5126-5137
-
-
Lonning, P.E.1
Geisler, J.2
Krag, L.E.3
Erikstein, B.4
Bremnes, Y.5
Hagen, A.I.6
Schlichting, E.7
Lien, E.A.8
Ofjord, E.S.9
Paolini, J.10
Polli, A.11
Massimini, G.12
-
20
-
-
38549180762
-
Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer
-
suppl 8
-
Perez EA: Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol 18:viii26-viii35, 2007 (suppl 8)
-
(2007)
Ann Oncol
, vol.18
-
-
Perez, E.A.1
-
21
-
-
54849424382
-
Safety profiles of aromatase inhibitors and selective estrogen-receptor modulators in the treatment of early breast cancer
-
Yamamoto Y, Iwase H: Safety profiles of aromatase inhibitors and selective estrogen-receptor modulators in the treatment of early breast cancer. Int J Clin Oncol 13:384-394, 2008
-
(2008)
Int J Clin Oncol
, vol.13
, pp. 384-394
-
-
Yamamoto, Y.1
Iwase, H.2
-
22
-
-
79951789895
-
-
Minister for Health, Welfare, and Family Affairs, National Cancer Center: Goyang-si
-
Minister for Health, Welfare, and Family Affairs, National Cancer Center: Cancer Facts & Figures 2009 in the Republic of Korea. Goyang-si, 2009
-
(2009)
Cancer Facts & Figures 2009 in the Republic of Korea
-
-
-
23
-
-
58549110458
-
Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone
-
Jannuzzo MG, Di Salle E, Spinelli R, et al: Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone. Breast Cancer Res Treat 113:491-499, 2009
-
(2009)
Breast Cancer Res Treat
, vol.113
, pp. 491-499
-
-
Jannuzzo, M.G.1
Di Salle, E.2
Spinelli, R.3
-
24
-
-
24044523821
-
Use of goserelin in the treatment of breast cancer
-
DOI 10.1586/14737140.5.4.591
-
Rody A, Loibl S, von Minckwitz G, et al: Use of goserelin in the treatment of breast cancer. Expert Rev Anticancer Ther 5:591-604, 2005 (Pubitemid 41223268)
-
(2005)
Expert Review of Anticancer Therapy
, vol.5
, Issue.4
, pp. 591-604
-
-
Rody, A.1
Loibl, S.2
Von, M.G.3
Kaufmann, M.4
-
25
-
-
0032805333
-
Premenopausal breast cancer patients treated with a gonadotropin- releasing hormone analog alone or in combination with an aromatase inhibitor: A comparative endocrine study
-
Celio L, Martinetti A, Ferrari L, et al: Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: A comparative endocrine study. Anticancer Res 19:2261-2268, 1999 (Pubitemid 29392532)
-
(1999)
Anticancer Research
, vol.19
, Issue.3 B
, pp. 2261-2268
-
-
Celio, L.1
Martinetti, A.2
Ferrari, L.3
Buzzoni, R.4
Mariani, L.5
Miceli, R.6
Seregni, E.7
Procopio, G.8
Cassata, A.9
Bombardieri, E.10
Bajetta, E.11
-
26
-
-
45749089797
-
Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole
-
DOI 10.1634/theoncologist.2007-0206
-
Brufsky A, Bundred N, Coleman R, et al: Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 13:503-514, 2008 (Pubitemid 351872868)
-
(2008)
Oncologist
, vol.13
, Issue.5
, pp. 503-514
-
-
Brufsky, A.1
Bundred, N.2
Coleman, R.3
Lambert-Falls, R.4
Mena, R.5
Hadji, P.6
Jin, L.7
Schenk, N.8
Ericson, S.9
Perez, E.A.10
-
27
-
-
67649804881
-
Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results
-
Brufsky AM, Bosserman LD, Caradonna RR, et al: Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 9:77-85, 2009
-
(2009)
Clin Breast Cancer
, vol.9
, pp. 77-85
-
-
Brufsky, A.M.1
Bosserman, L.D.2
Caradonna, R.R.3
-
28
-
-
0035312469
-
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases
-
Berenson JR, Rosen LS, Howell A, et al: Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91:1191-1200, 2001
-
(2001)
Cancer
, vol.91
, pp. 1191-1200
-
-
Berenson, J.R.1
Rosen, L.S.2
Howell, A.3
|